💊nutraceuticals ubiquitous and “assumed” by many pts to be heart healthy.
💊💰💸industry
💊 SPORT ➡️ compared to rosuva and placebo, do they impact biomarkers? jacc.org/doi/abs/10.101… @kewatson@ErinMichos@ljlaffin 1/
N=199, randomized single blind
💊 lipid, hsCRP, CMP. Baseline and at 28 days.
💊 1° risk, age 40-75, LDL-C 70-189, borderline to upper intermediate risk (5-20%, estimated 10 yr event)
💊 1° endpt: %LDL-C change vs rosuva
💊2° endpt: biomarkers vs rosuva; vs placebo #aha22 2/
💊 most were at least 7.5% 10 year risk
💊 nice representation of 💃🏽
💊 LDL-C >100 (~125); hsCRP <2.0
💊 no surprise, rosuva 5 mg is potent, LDL-C %change 37 👊🏾👍🏾
💊 good to know: RYR, 6%’ish. Others nominal
💊 2° - no surprise for rosuva in TC, trigs, hdl-c
💊 not 1° or 2° endpt, but interesting side effects… looking at you musculoskeletal effects on statin - big ZERO. Placebo on other hand, 8% - samson trial anyone 😉
Summary:
Thanks for a simple, elegant study that helps in #SDM RE: statin and certain supplements #aha22 6/6
• • •
Missing some Tweet in this thread? You can try to
force a refresh
🐟interesting drop out rate/protocol deviation, covid era?
🐟LDL-C baseline, similar to reduce it
🐟EPA median 46 ug/mL, higher than reduce it (26), lower than Jelis (96).
🐟hsCRP ~0.40 2/ #aha22
Throwing dollars at “health”doesn’t = improved health. This is staggering. We need to change what and how we deliver #Healthcare and where the $$ are spent #aha22